$5.780
+0.102 (+1.76%)終値時点
INCR のニュース
INCR のイベント
InterCure Reaches $77M Settlement with Israeli Tax Authorities
InterCure announced that it has reached a final settlement with the Israeli Tax Authorities and Compensation Fund regarding the company's claim for indirect damages resulting from the October 7, 2023 attacks and the subsequent war. Under the final settlement, aggregated compensation for the indirect damage covered by the claim has been agreed at a total of approximately $77M. Before the final settlement, the company's total claim for indirect damages was approximately over $100M and the company previously received approximately $34M in advance payments related to the claim. Since the attacks, InterCure raised approximately $20M from major shareholders and a leading pharma fund and committed significant resources to the recovery of the company and the rehabilitation of the Nir Oz facility, while continuing to serve its patient communities and executing global expansion. The company intends to accelerate the rehabilitation and restoration of the Nir Oz facility and return the facility to full operations as soon as practicable.
INC Research Trading Halted, News Pending
INC Research trading halted, news pending
InterCure Receives Nasdaq Compliance Notice
InterCure announced that the company received a written notice from Nasdaq indicating that the company was not in compliance with Nasdaq Listing Rule 5450, as the company's closing bid price for its ordinary shares, or ordinary shares, was below $1.00 per share for the last 30 consecutive business days. Pursuant to Nasdaq Listing Rule 5810, the company has been granted a 180-calendar day compliance period, or until August 24 to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the ordinary shares must meet or exceed $1.00 per share for at least 10 consecutive business days during the 180-calendar day compliance period. If the company is not in compliance by August 24, the company expects to be eligible for an additional 180-calendar day compliance period.
InterCure Expects Positive EBITDA for 2025
Adjusted EBITDA is expected to be positive in both the first and second halves of 2025, marking the Company's twelfth consecutive half-year of positive Adjusted EBITDA. Cash on hand of NIS 43M as of December 31, 2025. Alexander Rabinovich, CEO noted: "2025 marked a year of disciplined execution and renewed growth for InterCure. We delivered meaningful acceleration in the second half of the year with nearly 20% revenue growth and achieved our twelfth consecutive half-year of positive Adjusted EBITDA. The anticipated commencement of operations under the Botanico transaction and our strategic collaboration with Cannasoul are expected to further strengthen our pharmaceutical platform and global positioning. This marks another key milestone with our first significant revenues in the German market, as we expect continued execution of our global expansion strategy in Germany and additional markets throughout 2026. As regulatory frameworks continue to evolve, particularly in the United States and Europe, we believe InterCure is strategically positioned to leverage its vertically integrated model, scientific leadership, and international partnerships to drive long-term value for patients and shareholders."
InterCure and Cannasoul Forge Strategic Investment and Collaboration Partnerships
InterCure announced it has entered into a definitive Share Purchase Agreement and a Collaboration Agreement with Cannasoul R&D. The Share Purchase Agreement provides InterCure with a 28% ownership position in Cannasoul on a fully diluted basis and an exclusive path to increase its holdings to 51% within two years, while the Collaboration Agreement formalizes a partnership in research, development, and commercialization of evidence-based cannabis therapeutics.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。